Description
Levofloxacin, developed by Daiichi Sankyo, is used to treat bacterial infectious diseases such as community pneumonia, sinusitis, urinary tract infections. Levofloxacin tablets were approved in China in 1995, and Levofloxacin injection and oral regular-release liquids have entered China’s medical insurance. By the half-past of 2021, there are many manufacturers in China’s Levofloxacin market, among which Daiichi Sankyo Pharmaceutical (Beijing) accounts for the highest proportion of market share.
According to CRI’s market research, the sales value of Levofloxacin in the Chinese market from 2016 to 2019 has shown an overall upward trend. Due to the impact of the COVID-19 epidemic on the overall medical diagnosis and treatment services, the sales value of Levofloxacin in the Chinese market decreased to CNY 1.01 billion in 2020, with a year-on-year decrease of 28.23%. The CAGR of the sales value of Levofloxacin in the Chinese market is -4.75% from 2016 to 2020.
CRI expects that with the relief of the COVID-19 epidemic, the sales of Levofloxacin will have a restorative growth from 2021 to 2025. In addition, Levofloxacin has a broad antibacterial spectrum, strong antibacterial activity, high bioavailability, and good tissue cell permeability. Based on these advantages, the sales of Levofloxacin will grow steadily in the future. Further, the sales and sales volume of Levofloxacin used to treat bacterial infection will grow with the popularization and improvement of China’s medical and health services.
Topics Covered:
-The impact of COVID-19 on China’s Levofloxacin market
– Sales value of China’s Levofloxacin 2016-2020
– Competitive landscape of China’s Levofloxacin market
– Prices of Levofloxacin in China
– Prices of Levofloxacin in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Levofloxacin market
– Prospect of China’s Levofloxacin market from 2021 to 2025
